Загрузка...
PARP inhibitors combined with ionizing radiation induce different effects in melanoma cells and healthy fibroblasts
BACKGROUND: PARP inhibitors niraparib and talazoparib are FDA approved for special cases of breast cancer. PARP is an interesting repair protein which is frequently affected in cancer cells. We studied the combined action of talazoparib or niraparib with ionizing radiation in melanoma cells and heal...
Сохранить в:
| Опубликовано в: : | BMC Cancer |
|---|---|
| Главные авторы: | , , , , , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
BioMed Central
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7433076/ https://ncbi.nlm.nih.gov/pubmed/32811446 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-020-07190-9 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|